How to Buy Travere Therapeutics Stock
Travere Therapeutics Inc
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases.
Travere Therapeutics stock last closed at $62.76, down 3.06% from the previous day, and has increased 159.45% in one year. It has overperformed other stocks in the Biotechnology industry by 1.81 percentage points. Travere Therapeutics stock is currently +184.56% from its 52-week low of $22.06, and -8.69% from its 52-week high of $68.73.
At the moment, there are 94.26M shares of TVTX outstanding. The market value of TVTX is $5.92B. In the last 24 hours, 2.24M TVTX shares were traded.
How to Buy Travere Therapeutics Stock
Wondering how to invest in Travere Therapeutics stock? Here's how.
- Choose where to buy Travere Therapeutics stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Travere Therapeutics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Select your method of payment and add your information.
- Evaluate Travere Therapeutics stock: The Travere Therapeutics ticker symbol is TVTX. Is Travere Therapeutics stock a good investment? Should you buy shares of TVTX? How do TVTX's underlying business fundamentals look? Do top analysts think Travere Therapeutics is a good buy? Why has TVTX's stock price moved recently? (Hint: Our stock market research website can help you evaluate if TVTX is a good stock to buy).
- Place your TVTX buy order: Decide if you will purchase TVTX shares at the current market price or use a limit order to purchase TVTX shares at a given price.
- Watch your investment in TVTX: Create a watchlist to monitor your investment in Travere Therapeutics stock.
Step 1: Choose where to buy Travere Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy TVTX stock.
Our favorite brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world markets: From Tech to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen your brokerage, you need to fill out some personal info so you can buy TVTX stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start a new trading account.
- Send your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've created your account on a investment app, you need to deposit funds:
Watch this video walkthrough if you need help transferring money into your investment account.
Step 4: Evaluate Travere Therapeutics stock
Once you have chosen the best place to buy Travere Therapeutics stock, it's very important to analyze their stock prior to buying, so you can wrap your head around the risk as well as the upside.
Travere Therapeutics quick stats
TVTX Overview
WallStreetZen was built to help part-time investors perform better fundamental analysis quickly.
You can view all of the due diligence checks on TVTX's stock page.
How is TVTX stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge TVTX's fair value.
Using relative valuations measures:
- TVTX may be overvalued based on its P/B ratio of 241.25x, relative to Biotechnology industry P/B ratio of 5.28x
You can do more valuation analysis on TVTX's stock here.
A quick look at TVTX Financials
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the TVTX balance sheet.
- TVTX profit margin has gone up from -50.6% to -7.4% in the past year.
Negative Health Checks:
- TVTX has a relatively high debt to equity ratio of 31.6.
- Total TVTX debt is higher than 5 years ago, relative to shareholder equity.
- TVTX earnings of -$33.38M is not enough to cover its interest payments.
- There are more long-term liabilities than short-term assets on the TVTX balance sheet.
- TVTX's operating cash flow of $92.70M allows it to safely service it's debt of $616.91M.
Is TVTX stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 9 sell side analysts who give forecasts on TVTX, the consensus analyst rating on Travere Therapeutics is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest TVTX Analyst Ratings
Vamil Divan, a top 4% analyst from Guggenheim maintains TVTX with a strong buy rating and raises their TVTX price target from $65.00 to $75.00, on Aug 5, 2026.
Guggenheim's Vamil Divan raised their price target on Travere Therapeutics (NASDAQ: TVTX) by 15.4% from $65 to $75 on 2026/08/05. The analyst maintained their Strong Buy rating on the stock.
Travere Therapeutics reported its Q2 2026 earnings.
Raising their price target, Divan attributed the move to the quarter's results and a follow-up conversation with company management.
Earnings Report
For Q2 2026, Travere Therapeutics reported:
- EPS of $(0.37), which missed the Zacks Consensus Estimate and Q2 2025, both $(0.14).
- Revenue of $169.58M, which beat the Zacks Consensus Estimate by 10.16% and Q2 2025's $114.45M.
Management did not provide financial guidance in its press release.
President & CEO Eric Dube, Ph.D., commented: “With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth.
“Our performance reflects the strength of the company we are building and the disciplined execution of our teams as we continue to deliver on our strategy.
"During the quarter, we made meaningful progress across each of our strategic growth pillars, driving continued commercial momentum for FILSPARI, including a promising early launch in FSGS and continued strength in IgA nephropathy, as well as advancing our pegtibatinase program toward its pivotal Phase 3 readout and expanding our rare kidney disease pipeline through the addition of civorebrutinib.
"Together, these strengthen the durability of our growth profile, diversify our pipeline and reinforce our commitment to delivering meaningful new therapies for people living with rare diseases.”
Mohit Bansal, a top 11% analyst from Wells Fargo maintains TVTX with a strong buy rating and raises their TVTX price target from $50.00 to $65.00, on Jun 12, 2026.
Joseph Pantginis, a top 6% analyst from HC Wainwright & Co. maintains TVTX with a buy rating and raises their TVTX price target from $57.00 to $67.00, on Jun 2, 2026.
Anupam Rama, a top 7% analyst from JP Morgan maintains TVTX with a strong buy rating and lowers their TVTX price target from $44.00 to $41.00, on Mar 25, 2026.
You can dive deeper into what analysts are saying on the Travere Therapeutics stock forecast page.
Metrics for Advanced TVTX Traders
TVTX Performance Numbers
Last year, TVTX revenue was $591.33M. In the last five year, TVTX's revenue has grown by 23.7% per year. This was slower than the Biotechnology industry average of 24.78%.
You can analyze TVTX's earnings and revenue performance here.
Who is buying/selling TVTX?
In the past 12 months, executives and large shareholders at TVTX have sold more shares than they have bought.
Eric M. Dube, CEO of TVTX, was the latest TVTX insider to buy. They bought $2,532,226.62 worth of TVTX shares on Sep 17, 2026.
Dig into more about who owns TVTX shares here.
Can I get consistent income from TVTX stock?
No, Travere Therapeutics doesn't provide an income stream by paying out dividends.
TVTX Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your TVTX buy order
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount limit, use a limit order.
Click the Open button and eToro will place the order.
If you need additional info about buying stocks on eToro, click the helpful video below:
Step 6: Watch your investment in TVTX
Now that you own some shares in TVTX, you'll want to keep up with your new investment.
Make a watchlist to monitor your TVTX stock.
TVTX Feed
How to Buy Stock in Travere Therapeutics
To summarize, here are the 6 steps you need to take to buy Travere Therapeutics stock right now:
- Choose where to buy Travere Therapeutics stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Evaluate Travere Therapeutics stock
- Place your TVTX buy order
- Watch your investment in TVTX
If you need a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get updates on your investment in Travere Therapeutics, click below.
Other Stock Buying Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.